Overview

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
0
Participant gender:
All
Summary
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Amgen
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Antibodies, Monoclonal
Camptothecin
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Irinotecan
Panitumumab
Sunscreening Agents
Criteria
Inclusion Criteria:

- Patients with unresectable metastatic adenocarcinoma of the colon or rectum that
cannot, in the opinion of the investigator, be cured by surgical resection at the time
of randomization;

- Patients who have failed first line treatment containing fluoropyrimidine and
oxaliplatin based chemotherapy with or without bevacizumab for mCRC.

Exclusion Criteria:

• Prior irinotecan use for the treatment of mCRC.